Medical Condition News

RSS

High cholesterol in midlife does not increase risk for Alzheimer's disease among women

High cholesterol levels in middle age do not appear to increase women's risk of developing Alzheimer's disease and other forms of dementia later in life, new Johns Hopkins-led research finds, despite a body of scientific evidence long suggesting a link between the two.

11 Nov 2010

Researchers identify molecular cascade that drives sprouting in brain after stroke

A stroke wreaks havoc in the brain, destroying its cells and the connections between them. Depending on its severity and location, a stroke can impact someone's life forever, affecting motor activity, speech, memories, and more.

11 Nov 2010

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today presented additional interim data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement. The data were presented at the Chemotherapy Foundation Symposium being held in New York City.

11 Nov 2010

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Newly published research by scientists at the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, sheds light on a poorly understood, acute illness called Immune Reconstitution Inflammatory Syndrome (IRIS) that develops in some HIV-infected individuals soon after they begin antiretroviral therapy.

11 Nov 2010

Consumption of fructose-rich beverages can increase gout risk in women

Consumption of fructose-rich beverages, such as sugar-sweetened sodas and orange juice is associated with an increased risk of gout among women, although their contribution to the risk of gout in the population is likely modest because of the low incidence rate among women, according to a study that will appear in the November 24 print edition of JAMA.

11 Nov 2010

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

Cortex Pharmaceuticals, Inc. announced that it had been notified by Les Laboratoires Servier ("Servier"), France's largest privately held pharmaceutical company, of their intent to move forward into Phase I clinical studies with the jointly-discovered High Impact AMPAKINE® compound S47445 (CX1632).

11 Nov 2010

MCAN invests $4 million to improve asthma management in four high risk cities

The Merck Childhood Asthma Network, Inc. (MCAN), today announced it is targeting four high risk cities with nearly $4 million for programs that will combine evidence-based science, case management and asthma trigger removal plans to manage a disease that requires more than the right medical care.

11 Nov 2010

Genetic constitution can influence changes in tumor growth: Study

The genes we possess not only determine the color of our eyes and hair and how our bodies grow, they might also influence the changes that occur in tumors when we develop cancer.

11 Nov 2010

Media has misrepresented facts about Omega-3 DHA Alzheimer's study, says Ocean Nutrition Canada

Several media outlets published articles last week suggesting that Omega-3 fish oil supplements fail to show positive results for Alzheimer's patients. This reporting by media outlets came after the Journal of the American Medical Association (JAMA) published the study "Docosahexaenoic Acid Supplementation and Cognitive Decline in Alzheimer Disease: A Randomized Trial", where researchers reported that "Supplementation with DHA compared with placebo did not slow the rate of cognitive and functional decline in patients with mild to moderate Alzheimer disease."

11 Nov 2010

Exhausted neurons die prematurely and trigger disease symptoms

We all know that living a stressful lifestyle can take its toll, making us age faster and making us more susceptible to the cold going around the office.

11 Nov 2010

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Hygeia Therapeutics, Inc. announced today the successful completion of a series of preclinical studies for HYG-102, their lead product for the treatment of vulvar and vaginal atrophy (VVA) and age-related skin fragility. HYG-102 is the lead biodegradable estrogenic candidate in a portfolio of 23 similar compounds licensed from the laboratory of Dr. Richard Hochberg of Yale University.

11 Nov 2010

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Aeterna Zentaris Inc. today announced that it will present a poster on Phase 2 results for AEZS-108 in advanced endometrial cancer at the 22nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics to be held at the Berlin Estrel Hotel and Convention Centre in Berlin, Germany November 16 through 19, 2010.

11 Nov 2010

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Resolve Therapeutics, LLC today announced that it has entered into an exclusive license with the University of Washington for certain biologic compounds and technology developed to treat autoimmune diseases including systemic lupus erythematosus (SLE).

11 Nov 2010

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

Officials of Kylin Therapeutics Inc. announces that they received a therapeutic discovery project grant from the U.S. Internal Revenue Service that will advance the company's pRNAi nanoparticle cancer treatment research.

11 Nov 2010

New discovery can develop diagnostic test to identify gene mutation in AML

Decoding the DNA of a woman who died of acute myeloid leukemia (AML) has led researchers at Washington University School of Medicine in St. Louis to a gene that they found to be commonly altered in many patients who died quickly of the disease.

11 Nov 2010

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Amgen Inc. today announced the publication of results from the first open-label study to compare Nplate® (romiplostim) treatment to standard of care therapies (SOC) in non-splenectomized adult patients with chronic immune thrombocytopenia (ITP). The study results, which were published today in the New England Journal of Medicine (NEJM), show that both the incidence of treatment failure and need for splenectomy were reduced among the Nplate-treated patients.

11 Nov 2010

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Watson Pharmaceuticals, Inc. today announced that the U.S. pilot study evaluating Uracyst (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

11 Nov 2010

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

A Finnish study published in the November 11, 2010 issue of the New England Journal of Medicine confirms the hypothesis that infant feeding plays a role in the initiation of the disease process leading to type 1 diabetes in children carrying increased genetic disease risk.

11 Nov 2010

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

Contrary to earlier research, a new, long-term study suggests that cholesterol level in mid-life may not be linked to later development of Alzheimer's disease, according to a study published in the November 10, 2010, online issue of Neurology, the medical journal of the American Academy of Neurology. However, the results suggest that large decreases in cholesterol levels in old age could be a better predictor of developing the memory-robbing disease.

11 Nov 2010

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

A 'magic bullet' designed by pharmaceutical scientists at an English university could eradicate the side effects of a drug used to treat a rare genetic disease. Researchers at the University of Sunderland have chemically modified a drug used to treat cystinosis a disease which occurs when the body's mechanism to remove excess cystine (an amino acid) breaks down, leading to kidney problems and eventually affecting other organs to remove unpleasant side effects such as nausea, vomiting, severe halitosis, body odour and a noxious taste.

11 Nov 2010

Medical Condition News

High cholesterol in midlife does not increase risk for Alzheimer's disease among women

Researchers identify molecular cascade that drives sprouting in brain after stroke

Alnylam Pharmaceuticals presents ALN-VSP Phase I data for liver cancer at Chemotherapy Foundation Symposium

New study sheds light on Immune Reconstitution Inflammatory Syndrome

Consumption of fructose-rich beverages can increase gout risk in women

Cortex applauds Servier for intent to move High Impact AMPAKINE compound into Phase I clinical studies

MCAN invests $4 million to improve asthma management in four high risk cities

Genetic constitution can influence changes in tumor growth: Study

Media has misrepresented facts about Omega-3 DHA Alzheimer's study, says Ocean Nutrition Canada

Exhausted neurons die prematurely and trigger disease symptoms

Hygeia completes HYG-102 preclinical studies for vulvar and vaginal atrophy, and age-related skin fragility

Aeterna Zentaris to present AEZS-108 Phase 2 results for endometrial cancer at EORTC-NCI-AACR Symposium

Resolve Therapeutics enters license with University of Washington for autoimmune disease treatment

Kylin receives $250,000 IRS award to advance pRNAi nanoparticle cancer treatment research

New discovery can develop diagnostic test to identify gene mutation in AML

Nplate reduces treatment failure and splenectomies in adults with chronic immune thrombocytopenia

Watson’s Uracyst pilot study for interstitial cystitis fails to demonstrate efficacy endpoints

Dietary intervention reduces emergence of diabetes-predictive autoantibodies by 50%

Study suggests mid-life cholesterol level may not linked to later development of Alzheimer's disease

New 'magic bullet' can eradicate side effects of drug used to treat cystinosis

Advancing benzodiazepine detection

The Surgeon-Scientist Pioneering Regenerative Engineering

Leveraging the Radian ASAP in standard casework

Latest News